289 related articles for article (PubMed ID: 14602172)
1. Cyclosporine A delivery to the eye: a pharmaceutical challenge.
Lallemand F; Felt-Baeyens O; Besseghir K; Behar-Cohen F; Gurny R
Eur J Pharm Biopharm; 2003 Nov; 56(3):307-18. PubMed ID: 14602172
[TBL] [Abstract][Full Text] [Related]
2. Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies.
Di Tommaso C; Bourges JL; Valamanesh F; Trubitsyn G; Torriglia A; Jeanny JC; Behar-Cohen F; Gurny R; Möller M
Eur J Pharm Biopharm; 2012 Jun; 81(2):257-64. PubMed ID: 22445900
[TBL] [Abstract][Full Text] [Related]
3. Improving the topical ocular pharmacokinetics of lyophilized cyclosporine A-loaded micelles: formulation, in vitro and in vivo studies.
Yu Y; Chen D; Li Y; Yang W; Tu J; Shen Y
Drug Deliv; 2018 Nov; 25(1):888-899. PubMed ID: 29631468
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in ocular drug delivery.
Achouri D; Alhanout K; Piccerelle P; Andrieu V
Drug Dev Ind Pharm; 2013 Nov; 39(11):1599-617. PubMed ID: 23153114
[TBL] [Abstract][Full Text] [Related]
5. Silk Fibroin Formed Bioadhesive Ophthalmic Gel for Dry Eye Syndrome Treatment.
Hao T; Tang L; Xu Q; Wang W; Li Z; Shen Y; Xu B; Luo H; Li Q; Wang J; Zhang J
AAPS PharmSciTech; 2024 Apr; 25(5):92. PubMed ID: 38684590
[TBL] [Abstract][Full Text] [Related]
6. Semifluorinated alkanes as a liquid drug carrier system for topical ocular drug delivery.
Dutescu RM; Panfil C; Merkel OM; Schrage N
Eur J Pharm Biopharm; 2014 Sep; 88(1):123-8. PubMed ID: 24844949
[TBL] [Abstract][Full Text] [Related]
7. Ocular biocompatibility of novel Cyclosporin A formulations based on methoxy poly(ethylene glycol)-hexylsubstituted poly(lactide) micelle carriers.
Di Tommaso C; Torriglia A; Furrer P; Behar-Cohen F; Gurny R; Möller M
Int J Pharm; 2011 Sep; 416(2):515-24. PubMed ID: 21219997
[TBL] [Abstract][Full Text] [Related]
8. Ocular absorption of cyclosporine A from liposomes incorporated into collagen shields.
Pleyer U; Elkins B; Rückert D; Lutz S; Grammer J; Chou J; Schmidt KH; Mondino BJ
Curr Eye Res; 1994 Mar; 13(3):177-81. PubMed ID: 8194366
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts.
Lallemand F; Schmitt M; Bourges JL; Gurny R; Benita S; Garrigue JS
Eur J Pharm Biopharm; 2017 Aug; 117():14-28. PubMed ID: 28315447
[TBL] [Abstract][Full Text] [Related]
10. [Topical cyclosporine in ophthalmology: Pharmacology and clinical indications].
Levy O; Labbé A; Borderie V; Laroche L; Bouheraoua N
J Fr Ophtalmol; 2016 Mar; 39(3):292-307. PubMed ID: 26997607
[TBL] [Abstract][Full Text] [Related]
11. Cationized hyaluronic acid coated spanlastics for cyclosporine A ocular delivery: Prolonged ocular retention, enhanced corneal permeation and improved tear production.
Liu Y; Wang Y; Yang J; Zhang H; Gan L
Int J Pharm; 2019 Jun; 565():133-142. PubMed ID: 31075435
[TBL] [Abstract][Full Text] [Related]
12. Ocular irritation and cyclosporine A distribution in the eye tissues after administration of Solid Lipid Microparticles in the rabbit model.
Wolska E; Sznitowska M; Chorążewicz J; Szerkus O; Radwańska A; Markuszewski MJ; Kaliszan R; Raczyńska K
Eur J Pharm Sci; 2018 Aug; 121():95-105. PubMed ID: 29777856
[TBL] [Abstract][Full Text] [Related]
13. Delivery of therapeutics for deep-seated ocular conditions - status quo.
Nguyen H; Eng S; Ngo T; Dass CR
J Pharm Pharmacol; 2018 Aug; 70(8):994-1001. PubMed ID: 29675844
[TBL] [Abstract][Full Text] [Related]
14. In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease.
Rodriguez-Aller M; Kaufmann B; Guillarme D; Stella C; Furrer P; Rudaz S; El Zaoui I; Valamanesh F; Di Tommaso C; Behar-Cohen F; Veuthey JL; Gurny R
Eur J Pharm Biopharm; 2012 Apr; 80(3):544-52. PubMed ID: 22155591
[TBL] [Abstract][Full Text] [Related]
15. Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs.
Agarwal P; Scherer D; Günther B; Rupenthal ID
Int J Pharm; 2018 Mar; 538(1-2):119-129. PubMed ID: 29339249
[TBL] [Abstract][Full Text] [Related]
16. Self-assembling colloidal system for the ocular administration of cyclosporine A.
Luschmann C; Tessmar J; Schoeberl S; Strauß O; Luschmann K; Goepferich A
Cornea; 2014 Jan; 33(1):77-81. PubMed ID: 24162754
[TBL] [Abstract][Full Text] [Related]
17. Development and characterization of Cyclosporine A loaded nanoparticles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies.
Aksungur P; Demirbilek M; Denkbaş EB; Vandervoort J; Ludwig A; Unlü N
J Control Release; 2011 May; 151(3):286-94. PubMed ID: 21241752
[TBL] [Abstract][Full Text] [Related]
18. Prodrugs and nanomicelles to overcome ocular barriers for drug penetration.
Gote V; Ansong M; Pal D
Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):885-906. PubMed ID: 32729364
[TBL] [Abstract][Full Text] [Related]
19. Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies.
Mandal A; Bisht R; Rupenthal ID; Mitra AK
J Control Release; 2017 Feb; 248():96-116. PubMed ID: 28087407
[TBL] [Abstract][Full Text] [Related]
20. Ocular delivery systems for poorly soluble drugs: an in-vivo evaluation.
Luschmann C; Herrmann W; Strauss O; Luschmann K; Goepferich A
Int J Pharm; 2013 Oct; 455(1-2):331-7. PubMed ID: 23867983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]